Treatment Trials

9 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
      Description

      This study is designed to assess the safety and preliminary activity of SBT6050 in combination with trastuzumab deruxtecan (Part 1) or tucatinib plus trastuzumab +/- capecitabine (Part 2). Participants will be enrolled into each Arm based on cancer diagnosis and prior therapies.

      Conditions
      HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal CancerHER2-expressing Non-small Cell Lung Cancer
      Talk to us
      TERMINATED
      DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
      Description

      The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.

      Conditions
      Non-Small Cell Lung Cancer
      Talk to us
      RECRUITING
      Phase 1 Open-Label Study BL-M17D1 w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
      Description

      The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.

      Conditions
      Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast CarcinomaHer2-PositiveHER2 Gene MutationGastroesophageal-junction CancerNon Small Cell Lung CancerEndometrial NeoplasmsPeritoneal CancerFallopian Tube CancerOvarian CancerUrothelial Carcinoma BladderSolid Tumor, AdultGastric Cancer
      Talk to us
      RECRUITING
      A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
      Description

      The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

      Conditions
      Breast CancerGastric CancerEsophageal CancerGastroesophageal CancerColorectal CancerEndometrial CancerNon-small Cell Lung CancerOvarian CancerUrothelial CarcinomaSalivary Gland CancerPancreatic CancerHER-2 Protein Overexpression
      Talk to us
      UNKNOWN
      A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
      Description

      A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies

      Conditions
      HER2 Positive Solid Tumors
      Talk to us
      COMPLETED
      ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
      Description

      ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702.

      Conditions
      Locally Advanced Solid TumorMetastatic CancerSolid TumorHER2-positive Gastric CancerHER2-positive Metastatic Breast Cancer
      Talk to us
      TERMINATED
      A First-in-human Study Using BDC-1001 As a Single Agent and in Combination with Nivolumab in Advanced HER2-Expressing Solid Tumors
      Description

      A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

      Conditions
      HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal CancerHER2-positive Gastroesophageal CancerHER2-positive Endometrial Cancer
      Talk to us
      COMPLETED
      Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
      Description

      This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).

      Conditions
      HER2-expressing Cancers
      Talk to us
      COMPLETED
      A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
      Description

      This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

      Conditions
      HER2-expressing Cancers
      Talk to us